Business Wire

MobileIron Announces Zero Trust Platform Making the World’s Most Ubiquitous Product – the Mobile Device – Your ID and Secure Access to the Enterprise

Share

MobileIron (NASDAQ:MOBL) introduces the industry’s first mobile-centric, zero trust security platform. MobileIron's mobile-centric strategy allows for continuous enforcement and protection of data, both on the device and on the network, with comprehensive correlation between the critical signals for zero trust: user, device, apps, networks, and threats. This makes the world’s most ubiquitous product – the mobile device – your ID and secure access to the enterprise. This platform goes beyond identity management and gateway approaches by utilizing a more comprehensive set of attributes before granting access.

With mobile devices as your ID, organizations replace the password with a secure and frictionless alternative, ushering in a new era of user authentication. MobileIron is introducing a revolutionary zero sign-on experience built on the company’s leading unified endpoint management (UEM) platform and powered by the MobileIron Access solution.

Zero sign-on completely eliminates passwords as the method for user authentication, replacing single sign-on, which still requires at least one username and password. MobileIron paved the way for a zero sign-on enterprise with its Access product in 2017, which enabled zero sign-on to cloud services on managed devices. Today’s announcement extends this capability, making passwordless access to cloud services available from any device, managed or unmanaged, using the mobile device as the user’s secure ID.

“Mobile is the center of our universe, both personally and professionally. With that comes a need for a mobile-centric enterprise-grade security solution,” said Simon Biddiscombe, CEO, MobileIron. “We are delivering that solution – making the mobile device your ID and access to the enterprise. And we didn’t stop there. We are eliminating passwords for any device, whether managed or unmanaged, because we think single sign-on is one sign-on too many.”

Zero sign-on solves three problems inherent in passwords. As Forrester Research analysts Andras Cser and Merritt Maxim explain: “First, passwords represent a security risk because they can be easily hacked, and password reuse can start an avalanche of breaches. Second, password-related reset costs generate significant operational support costs. Third, password authentication is often the source of a bad user experience, especially in mobile environments” (Forrester: Understand The State Of Identity And Access Management, 2018 To 2019 ). Zero sign-on eliminates the pain and expense of traditional user credentials, replacing it with a seamless, secure authentication alternative.

A passwordless enterprise has been an unfulfilled promise for years. In fact, according to an April 2019 IDG survey of security decision makers, 86% would do away with passwords if they could. The same survey found that nearly 9 out of 10 security leaders believe that, in the near future, mobile devices will serve as the digital ID to access enterprise services and data.

The MobileIron security platform is built on the foundation of award-winning and industry-leading unified endpoint management (UEM) capabilities with additional zero trust-enabling technologies, including zero sign-on (ZSO), multi-factor authentication (MFA), and mobile threat defense (MTD). Together, they enable a seamless, secure user experience by ensuring only authorized users, devices, apps, and services can access business resources.

MobileIron’s vision is to revolutionize enterprise authentication with a mobile ID and zero sign-on experience from any device, any OS, any location, to any service. Turning vision into reality, MobileIron’s zero sign-on for unmanaged devices will be available in June 2019 on iOS devices. These capabilities will extend to Android devices later this year. For more information, visit here.

About MobileIron

MobileIron is redefining enterprise security with the industry’s first mobile-centric, zero trust platform built on the foundation of unified endpoint management (UEM) to secure access and protect data across the perimeter-less enterprise. Over 17,000 customers, including the world’s largest financial institutions, intelligence agencies, and other highly regulated companies rely on MobileIron to enable a seamless and secure user experience by ensuring only authorized users, devices, apps, and services can access business resources. For more information, visit www.mobileiron.com.

Contact information

Marjaneh Ravai
MobileIron
mravai@mobileiron.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SHINE Creates Therapeutics Division, Will Attend 2019 European Association of Nuclear Medicine Conference12.10.2019 04:00:00 CESTPress release

SHINE Medical Technologies, LLC today announced the creation of a new division of the company — SHINE Therapeutics. The establishment of the division enhances the company’s ability to focus on filling critical future needs in the rapidly growing therapeutic isotope market, while continuing to leverage its radioisotope production expertise. The company’s Therapeutics division will initially focus on the development and commercialization of lutetium‑177, or Lu‑177, a therapeutic isotope that is combined with a disease-specific targeting molecule to treat cancer. Targeting molecules deliver Lu‑177 atoms to cancer sites throughout the body, where they directly irradiate cancer cells. The first Lu‑177-based targeted radiotherapy (for neuroendocrine tumors) reached the market in 2018. Many high-potential targeted molecules for the treatment of a range of other cancers with Lu-177 are currently under investigation. SHINE is also evaluating additional medical isotopes with therapeutic properti

Smart Taxation – A Step Towards a Fair, Efficient and Growth-Friendly European Taxation Approach11.10.2019 22:01:00 CESTPress release

In a rapidly changing global economy, smart taxation is essential to drive growth and economic prosperity. However, the European Union (EU) continues to fall behind as it persists with a one-size-fits all taxation system. This year’s GLOBSEC Tatra Summit hosts a Focus Group, bringing together international experts, looking to reshape and support a smarter European tax policy. Europe is at a crossroads in adapting its tax policy to the realities of today’s global economy. The EU plays a key role in overseeing national tax rules in some areas - particularly in relation to EU business and consumer policies. The institutional changeover marks a perfect opportunity for the Tatra Summit to place major topics on the radar of decision-makers and offer efficient recommendations. So now is the time to adapt the EU’s taxation model to be fit-for-purpose. With member states around the table, European fiscal authorities should design a model that does not have a disruptive impact on national needs

Clovis Oncology Announces Rubraca®▼ (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund11.10.2019 13:19:00 CESTPress release

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the National Institute for Health and Care Excellence (NICE) has recommended that women with relapsed ovarian cancer in England have access to rucaparib through the Cancer Drugs Fund (CDF).1 Rucaparib is available for use within the CDF as an option for the maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy in adults, based on the conditions outlined in the managed access agreement. "Ovacome welcomes the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” said Victoria Clare, CEO of Ovacome, a United Kingdom ovarian cancer charity focused on providing support to anyone affected by ovarian cancer. “It is vital that the exp

Yokogawa Releases Dynamic Real Time Optimizer, a New Solution in the OpreX Asset Operations and Optimization Family11.10.2019 02:00:00 CESTPress release

Yokogawa Electric Corporation (TOKYO:6841) announces the release of Dynamic Real Time Optimizer, a solution in the OpreXTM Asset Operations and Optimization family. Using a combination of first principles simulation and multivariable predictive control technology, the Dynamic Real Time Optimizer software helps to optimize plant operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005009/en/ Operating window of Dynamic Real Time Optimizer (Graphic: Yokogawa Electric Corporation) This integrated solution is based on Yokogawa’s advanced process control technologies and industry knowledge and simulation technologies developed by KBC Advanced Technologies Limited (KBC, CEO: Andrew Howell), a UK-based Yokogawa subsidiary. This solution enables plants to quickly respond to dynamically changing oil market and product market conditions and improve both productivity and profitability. Development Background Advanced proces

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in FINCH 1 and FINCH 3 Studies in Rheumatoid Arthritis10.10.2019 22:00:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191010005875/en/ “We are encouraged by the durability of both the efficacy and safety profiles of filgotinib seen in these studies,” said John Sundy, MD, PhD, Senior Vice President, Inflammation and Respiratory Diseases, Gilead Sciences. “These data suggest that filgotinib if approved, may play an important role in helping people living with rheumatoid arthritis achieve sustained, clinically meaningful responses.” “The

Gilead Sciences to Release Third Quarter 2019 Financial Results on Thursday, October 24, 201910.10.2019 20:05:00 CESTPress release

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the con